 Cytokinetics Incorporated NASDAQ: CYTK announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with heart failure with reduced ejection fraction HFrEF. Data were presented at the American College of Cardiologys Annual Scientific Session. 